+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Diabetic Nephropathy Market and Forecast Analysis to 2026

  • ID: 3797413
  • Drug Pipelines
  • 236 pages
  • Datamonitor Healthcare
1 of 3
Disease Overview
Diabetic nephropathy, also known as diabetic kidney disease, is caused by damage to small blood vessels which can cause the kidneys to be less efficient in their blood filtration role or to fail altogether. The disease is a clinical syndrome characterized by albuminuria, decline in glomerular filtration rate, and elevated arterial blood pressure. Up to 50% of diabetics with a disease duration of over 20 years have diabetic nephropathy.

Market Snapshot
  • An ADA/EASD consensus report will help spur use of SGLT-2 inhibitors in DN patients.
  • Survey of 216 physicians in the US, Japan, and five major EU markets sheds light on prescribing patterns.
  • In parallel with diabetes, an increase in the prevalence burden of diabetic nephropathy cases is expected during 2017–37.
  • In-depth analysis of drug classes used for the treatment of diabetic nephropathy in the US, Japan, and five major EU markets.
  • Drugs with a cardiovascular benefit will have an advantage in DN.
Note: Product cover images may vary from those shown
2 of 3
FORECAST: DIABETIC NEPHROPATHY (Published on 07 February 2019)
Overview
Recent Forecast Updates
Market Dynamics And Pipeline Assessment
Forecast
Market Definition And Methodology
Bibliography
Primary Research Methodology
Product Profile (Late Stage): Farxiga
Product Profile (Late Stage): Invokana
Product Profile (Late Stage): Jardiance
Product Profile (Late Stage): Finerenone

TREATMENT: DIABETIC NEPHROPATHY (Published on 05 February 2018)
Overview
Executive Summary
Primary Research Methodology
Disease Definition And Diagnosis
Patient Segmentation
Guideline Recommendations
Prescribing Trends

EPIDEMIOLOGY: DIABETIC NEPHROPATHY (Published on 30 October 2018)
Overview
Disease Background
Methodology
Forecast
Bibliography
Appendix: Additional Sources

MARKETED DRUGS: DIABETIC NEPHROPATHY (Published on 07 February 2019)
Overview
Executive Summary
Ace Inhibitors
Angiotensin Ii Receptor Blockers

PIPELINE: DIABETIC NEPHROPATHY (Published on 07 February 2019)
Overview
Clinical Pipeline Overview
Target Product Profile
Clinical Trial Design
Recently Discontinued Drugs
Additional Pharma Intelligence Pipeline Resources
Product Profile (Late Stage): Farxiga
Product Profile (Late Stage): Invokana
Product Profile (Late Stage): Jardiance
Product Profile (Late Stage): Finerenone

LIST OF FIGURES
Figure 1: Diabetic nephropathy – current and future market dynamics analysis
Figure 2: The authors assessment summary of key marketed and pipeline drugs for diabetic nephropathy
Figure 3: Presence of self-reported cardiovascular conditions among diabetics in the US, according to renal stage and albuminuria
Figure 4: SGLT-2 inhibitor CVOT meta-analysis, change in risk of CV death versus placebo
Figure 5: Diabetic nephropathy novel treatment market sales across the US, Japan, and five major EU markets, by country, 2017–26
Figure 6: Diabetic nephropathy sales of specific drug franchises across the US, Japan, and five major EU markets, 2025 (second to last year of the forecast)
Figure 7: Diabetic nephropathy novel treatment market sales in the US, 2017–26
Figure 8: Diabetic nephropathy novel treatment market sales in the US, individual franchises, 2017–26
Figure 9: Diabetic nephropathy novel treatment market sales in the five major EU markets, by country, 2017–26
Figure 10: Methodology flow for diabetic nephropathy
Figure 11: Price sources and calculations, by country
Figure 12: The authors drug assessment summary of Farxiga for diabetic nephropathy
Figure 13: The authors drug assessment summary of Farxiga for diabetic nephropathy
Figure 14: Farxiga sales for diabetic nephropathy across the US, Japan, and five major EU markets, by country, 2017–26
Figure 15: The authors drug assessment summary of Invokana for diabetic nephropathy
Figure 16: The authors drug assessment summary of Invokana for diabetic nephropathy
Figure 17: Invokana sales for diabetic nephropathy across the US, Japan, and five major EU markets, by country, 2017–26
Figure 18: The authors drug assessment summary of Jardiance for diabetic nephropathy
Figure 19: The authors drug assessment summary of Jardiance for diabetic nephropathy
Figure 20: Jardiance sales for diabetic nephropathy across the US, Japan, and five major EU markets, by country, 2017–26
Figure 21: The authors drug assessment summary of finerenone for diabetic nephropathy
Figure 22: The authors drug assessment summary of finerenone for diabetic nephropathy
Figure 23: Finerenone sales for diabetic nephropathy across the US, Japan, and five major EU markets, by country, 2017–26
Figure 24: Percentage of incident end-stage renal disease patients with diabetes as the primary cause
Figure 25: Patient segmentation by albuminuria and glomerular filtration rate, with US prevalence and risk of kidney outcomes
Figure 26: Type 2 diabetic patients receiving antihypertensives for treatment of diabetic nephropathy according to stage of renal impairment, by country
Figure 27: Type 2 diabetic patients receiving RAAS inhibitors for treatment of diabetic nephropathy according to stage of renal impairment, by country
Figure 28: Usage of ACE inhibitors, ARBs, and renin inhibitors for diabetic nephropathy, as a percentage of antihypertensives, among type 2 diabetics, by country
Figure 29: Antihypertensive monotherapy versus combination therapy used to treat diabetic nephropathy in type 1 and type 2 diabetics, by country
Figure 30: Antihypertensive monotherapy vs combination therapy used to treat diabetic nephropathy in type 2 diabetics, by renal impairment stage and country
Figure 31: Percentage of type 2 diabetic patients receiving antidiabetics according to stage of renal impairment, by country
Figure 32: Percentage of type 2 diabetic patients receiving metformin/selected fixed-dose combinations according to stage of renal impairment, by country
Figure 33: Percentage of type 2 diabetic patients receiving DPP-IV inhibitors (including metformin fixed-dose combinations), by stage of renal impairment and country
Figure 34: Ratio of prescribing of Januvia and Tradjenta in each stage of renal impairment compared to prescribing in patients without diabetic nephropathy, by country
Figure 35: Percentage of type 2 diabetic patients receiving SGLT-2 inhibitors (excluding fixed-dose combinations) according to stage of renal impairment, by country
Figure 36: Percentage of type 2 diabetic patients receiving GLP-1 agonists and fixed-ratio combinations with insulin, by stage of renal impairment and country
Figure 37: Percentage of type 2 diabetic patients receiving any insulin according to stage of renal impairment, by country
Figure 38: Percentage of type 2 diabetic patients receiving any insulin according to stage of renal impairment, PCPs only, by country
Figure 39: Percentage of type 2 diabetic patients receiving sulfonylureas according to stage of renal impairment, by country
Figure 40: Compliance rates of type 2 diabetics with antidiabetic medications according to renal impairment stage, by country
Figure 41: Trends in total prevalent cases of diabetic nephropathy in the US, Japan, and five major EU markets, by country, 2017–37
Figure 42: The authors drug assessment summary of Farxiga for diabetic nephropathy
Figure 43: The authors drug assessment summary of Farxiga for diabetic nephropathy
Figure 44: Farxiga sales for diabetic nephropathy across the US, Japan, and five major EU markets, by country, 2017–26
Figure 45: The authors drug assessment summary of Invokana for diabetic nephropathy
Figure 46: The authors drug assessment summary of Invokana for diabetic nephropathy
Figure 47: Invokana sales for diabetic nephropathy across the US, Japan, and five major EU markets, by country, 2017–26
Figure 48: The authors drug assessment summary of Jardiance for diabetic nephropathy
Figure 49: The authors drug assessment summary of Jardiance for diabetic nephropathy
Figure 50: Jardiance sales for diabetic nephropathy across the US, Japan, and five major EU markets, by country, 2017–26
Figure 51: The authors drug assessment summary of finerenone for diabetic nephropathy
Figure 52: The authors drug assessment summary of finerenone for diabetic nephropathy
Figure 53: Finerenone sales for diabetic nephropathy across the US, Japan, and five major EU markets, by country, 2017–26

LIST OF TABLES
Table 1: Exchange rates used for calculating prices
Table 2: Primary care physicians, diabetologists, and endocrinologists surveyed for the diabetic nephropathy primary research study, 2017
Table 3: Farxiga drug profile
Table 4: Farxiga Phase III trial in chronic kidney disease, including diabetic nephropathy
Table 5: Farxiga Phase II/III trial on UACR and glycemic control in diabetic nephropathy
Table 6: Farxiga for diabetic nephropathy – SWOT analysis
Table 7: Invokana drug profile
Table 8: Invokana Phase III trial in diabetic nephropathy
Table 9: Invokana for diabetic nephropathy – SWOT analysis
Table 10: Jardiance drug profile
Table 11: Jardiance Phase III trial in chronic kidney disease, including diabetic nephropathy
Table 12: Jardiance for diabetic nephropathy – SWOT analysis
Table 13: Finerenone drug profile
Table 14: Finerenone Phase III trials in diabetic nephropathy
Table 15: Finerenone Phase IIb (ARTS-DN) results in diabetic nephropathy
Table 16: Finerenone for diabetic nephropathy – SWOT analysis
Table 17: Primary care physicians, diabetologists, and endocrinologists surveyed for the diabetic nephropathy primary research study, 2017
Table 18: Guideline recommendations for blood pressure and glycemic control – kidney organizations
Table 19: Guideline recommendations for blood pressure and glycemic control – diabetes organizations
Table 20: Risk of cardiovascular death and end-stage renal disease according to albuminuria and eGFR (% per year)
Table 21: Proportion of US patients with diabetic nephropathy who are treated with antihypertensives/RAAS inhibitors, by renal stage
Table 22: Sources used for diabetic nephropathy analysis in the US, Japan, and five major EU markets, by country
Table 23: Age-standardized diabetic nephropathy prevalence proportions, by country
Table 24: Segmentation of diabetic nephropathy into chronic kidney disease stage
Table 25: Sources used to segment diabetic nephropathy prevalent cases into chronic kidney disease stage, by country
Table 26: Total prevalent cases of diabetic nephropathy in the US, Japan, and five major EU markets, by country, 2017–37
Table 27: ACE inhibitors class overview
Table 28: ARBs class overview
Table 29: Major ARB trials in type 2 diabetic nephropathy patients with severe albuminuria
Table 30: Profiled pipeline products in development for diabetic nephropathy
Table 31: Cozaar drug profile
Table 32: Cozaar pivotal trial data in diabetic nephropathy
Table 33: Atrasentan drug profile
Table 34: Atrasentan Phase III trial in diabetic nephropathy
Table 35: Farxiga drug profile
Table 36: Farxiga Phase III trial in chronic kidney disease, including diabetic nephropathy
Table 37: Farxiga Phase II/III trial on UACR and glycemic control in diabetic nephropathy
Table 38: Farxiga for diabetic nephropathy – SWOT analysis
Table 39: Invokana drug profile
Table 40: Invokana Phase III trial in diabetic nephropathy
Table 41: Invokana for diabetic nephropathy – SWOT analysis
Table 42: Jardiance drug profile
Table 43: Jardiance Phase III trial in chronic kidney disease, including diabetic nephropathy
Table 44: Jardiance for diabetic nephropathy – SWOT analysis
Table 45: Finerenone drug profile
Table 46: Finerenone Phase III trials in diabetic nephropathy
Table 47: Finerenone Phase IIb (ARTS-DN) results in diabetic nephropathy
Table 48: Finerenone for diabetic nephropathy – SWOT analysis
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
Note: Product cover images may vary from those shown
Order Online - visit: https://www.researchandmarkets.com/reports/3797413
Adroll
adroll